Autolus Therapeutics (AUTL) Total Non-Current Liabilities (2017 - 2025)

Autolus Therapeutics (AUTL) has 8 years of Total Non-Current Liabilities data on file, last reported at $410.5 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities rose 15.63% year-over-year to $410.5 million; the trailing twelve-month figure through Dec 2025 stood at $410.5 million (up 15.63% YoY), and the FY2025 full-year result was $410.5 million, up 15.63% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $410.5 million, up from $396.0 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $410.5 million in Q4 2025 and bottomed at $92.1 million in Q4 2021.
• The 5-year median for Total Non-Current Liabilities is $263.6 million (2023), against an average of $258.0 million.
• The widest annual swing landed in 2021, when Total Non-Current Liabilities advanced 9.39%; it then soared 123.01% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $92.1 million in 2021, then soared by 107.88% to $191.5 million in 2022, then soared by 37.64% to $263.6 million in 2023, then soared by 34.69% to $355.0 million in 2024, then climbed by 15.63% to $410.5 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $410.5 million (Q4 2025), $396.0 million (Q3 2025), and $374.0 million (Q2 2025), per Business Quant data.

Peer Comparison